论文部分内容阅读
目的:检测血清S-100β蛋白在肺性脑病患者中的浓度,探讨其临床意义。方法:15例健康者为正常对照组,32例COPD无呼吸衰竭者,14例并发呼吸衰竭无肺性脑病者为病例对照组,22例肺性脑病患者为病例组,肺性脑病组分为轻型(9例)、中型(7)、重型(6例)3组。用双抗体夹心ELISA法检测血清中S-100β蛋白值,并进行比较分析。结果:血清中S-100β蛋白平均值:肺性脑病组(15.79±7.56μg/L)和COPD并发呼吸衰竭无肺性脑病组(11.20±4.68μg/L)显著高于COPD不并发呼吸衰竭组(7.45±4.40μg/L)和正常对照组(5.46±3.22μg/L)(P<0.05)。肺性脑病中,中型(18.18±5.19μg/L)和重型(21.64±9.56μg/L)显著高于轻型(10.03±2.15μg/L)(P<0.05),重型和中型无统计学意义(P>0.05)。结论:检测血清S-100β蛋白有助于了解有否发生脑损害并且有助于反应脑损害的程度。
Objective: To detect the concentration of serum S-100β protein in patients with pulmonary encephalopathy and to explore its clinical significance. Methods: Fifteen healthy controls were normal control group, 32 patients with COPD without respiratory failure, 14 cases with respiratory failure without pulmonary encephalopathy as case control group, 22 cases with pulmonary encephalopathy as case group and pulmonary encephalopathy as Light (9 cases), medium (7), heavy (6 cases) 3 groups. Serum S-100β protein levels were detected by double antibody sandwich ELISA and compared. Results: The average S-100β protein in serum was significantly higher in patients with pulmonary encephalopathy (15.79 ± 7.56μg / L) and non-pulmonary encephalopathy with COPD (11.20 ± 4.68μg / L) than those without COPD (7.45 ± 4.40μg / L) and normal control group (5.46 ± 3.22μg / L) (P <0.05). Pulmonary encephalopathy was significantly (18.18 ± 5.19μg / L) and heavier (21.64 ± 9.56μg / L) than light (10.03 ± 2.15μg / L) (P <0.05) P> 0.05). Conclusion: Detecting serum S-100β protein helps to understand whether brain damage has occurred and helps to reflect the extent of brain damage.